Literature DB >> 22408046

Mosquirix (RTS,S): a novel vaccine for the prevention of Plasmodium falciparum malaria.

Kyle J Wilby1, Tim T Y Lau, Samuel E Gilchrist, Mary H H Ensom.   

Abstract

OBJECTIVE: To summarize and evaluate the literature for Mosquirix (RTS,S) and provide insight into the therapeutic and economic controversies of this novel malaria vaccine candidate. DATA SOURCES: A systematic literature search was performed using the terms Mosquirix; RTS,S; malaria; vaccine; and Plasmodium in MEDLINE (1948-November 2011), EMBASE (1980-November 2011), International Pharmaceutical Abstracts (1970-November 2011), Google, and Google Scholar. STUDY SELECTION AND DATA EXTRACTION: Clinical trials describing vaccine development, pharmacology, pharmacokinetics, efficacy, and safety were reviewed. For efficacy, clinical trials were reviewed that reported acquisition of malarial disease. Information regarding study design, population, study period, baseline characteristics, clinical outcomes, results, and assessors of quality was extracted. DATA SYNTHESIS: Five randomized controlled trials and 4 follow-up extension studies were identified. In Phase 2 trials, vaccine efficacy rates were 33-65% in infants and 30-53% in children for preventing the first episode of clinical disease. In Phase 3 trials, vaccine efficacy was 56% in children aged 5-17 months. RTS,S reduced the number of clinical malaria episodes and prevented severe malaria in several studies. The follow-up period for vaccine efficacy ranged from 6 to 45 months. RTS,S 25 μg is administered intramuscularly as 3 injections given 1 month apart for infants and children. RTS,S appears to be generally well tolerated. A few cases of meningitis and seizures (within 7 days of vaccination) have been reported.
CONCLUSIONS: RTS,S has demonstrated efficacy and safety in Phase 1, 2, and 3 trials, and has the potential to decrease morbidity and mortality from malaria worldwide. Major challenges include determination of the duration of immunity, assessment of its cost-effectiveness, its use in special populations, and its dissemination in endemic regions. Pending further studies, RTS,S has the potential to become the benchmark as the first effective vaccine against malaria.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22408046     DOI: 10.1345/aph.1AQ634

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  13 in total

1.  Optimized Blanching Reduces the Host Cell Protein Content and Substantially Enhances the Recovery and Stability of Two Plant-Derived Malaria Vaccine Candidates.

Authors:  Stephan Menzel; Tanja Holland; Alexander Boes; Holger Spiegel; Johanna Bolzenius; Rainer Fischer; Johannes F Buyel
Journal:  Front Plant Sci       Date:  2016-02-17       Impact factor: 5.753

2.  Plant expression and characterization of the transmission-blocking vaccine candidate PfGAP50.

Authors:  Veronique Beiss; Holger Spiegel; Alexander Boes; Matthias Scheuermayer; Andreas Reimann; Stefan Schillberg; Rainer Fischer
Journal:  BMC Biotechnol       Date:  2015-12-01       Impact factor: 2.563

Review 3.  Self-assembling protein nanoparticles in the design of vaccines.

Authors:  Jacinto López-Sagaseta; Enrico Malito; Rino Rappuoli; Matthew J Bottomley
Journal:  Comput Struct Biotechnol J       Date:  2015-11-26       Impact factor: 7.271

4.  Vaccination for Disease Prevention and Control: the Necessity of Renewed Emphasis and New Approaches.

Authors:  Kwang Poo Chang
Journal:  J Immunol Immunotech       Date:  2014-07-09

5.  A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.

Authors:  Viswanathan Ramasamy; Upasana Arora; Rahul Shukla; Ankur Poddar; Rajgokul K Shanmugam; Laura J White; Melissa M Mattocks; Rajendra Raut; Ashiya Perween; Poornima Tyagi; Aravinda M de Silva; Siddhartha K Bhaumik; Murali Krishna Kaja; François Villinger; Rafi Ahmed; Robert E Johnston; Sathyamangalam Swaminathan; Navin Khanna
Journal:  PLoS Negl Trop Dis       Date:  2018-01-08

6.  Structure Based Docking and Molecular Dynamic Studies of Plasmodial Cysteine Proteases against a South African Natural Compound and its Analogs.

Authors:  Thommas M Musyoka; Aquillah M Kanzi; Kevin A Lobb; Özlem Tastan Bishop
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

7.  Analysis of the dose-dependent stage-specific in vitro efficacy of a multi-stage malaria vaccine candidate cocktail.

Authors:  Alexander Boes; Holger Spiegel; Robin Kastilan; Susanne Bethke; Nadja Voepel; Ivana Chudobová; Judith M Bolscher; Koen J Dechering; Rolf Fendel; Johannes F Buyel; Andreas Reimann; Stefan Schillberg; Rainer Fischer
Journal:  Malar J       Date:  2016-05-17       Impact factor: 2.979

8.  Application of a Scalable Plant Transient Gene Expression Platform for Malaria Vaccine Development.

Authors:  Holger Spiegel; Alexander Boes; Nadja Voepel; Veronique Beiss; Gueven Edgue; Thomas Rademacher; Markus Sack; Stefan Schillberg; Andreas Reimann; Rainer Fischer
Journal:  Front Plant Sci       Date:  2015-12-23       Impact factor: 5.753

9.  Recognizing the Importance of Vaccine Confidence.

Authors:  Steven Black
Journal:  EBioMedicine       Date:  2016-09-02       Impact factor: 8.143

10.  Adjuvant-induced Human Monocyte Secretome Profiles Reveal Adjuvant- and Age-specific Protein Signatures.

Authors:  Djin-Ye Oh; David J Dowling; Saima Ahmed; Hyungwon Choi; Spencer Brightman; Ilana Bergelson; Sebastian T Berger; John F Sauld; Matthew Pettengill; Alvin T Kho; Henry J Pollack; Hanno Steen; Ofer Levy
Journal:  Mol Cell Proteomics       Date:  2016-03-01       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.